Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

904 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis.
Zhou YF, Song SS, Tian MX, Tang Z, Wang H, Fang Y, Qu WF, Jiang XF, Tao CY, Huang R, Zhou PY, Zhu SG, Zhou J, Fan J, Liu WR, Shi YH. Zhou YF, et al. Among authors: zhou j, zhou py. J Immunother Cancer. 2021 Aug;9(8):e003031. doi: 10.1136/jitc-2021-003031. J Immunother Cancer. 2021. PMID: 34413167 Free PMC article.
Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma.
Tian MX, Luo LP, Liu WR, Deng W, Yin JC, Jin L, Jiang XF, Zhou YF, Qu WF, Tang Z, Wang H, Tao CY, Fang Y, Qiu SJ, Zhou J, Liu JF, Fan J, Shi YH. Tian MX, et al. Among authors: zhou j, zhou yf. Cancer Manag Res. 2019 Jun 5;11:5187-5195. doi: 10.2147/CMAR.S195964. eCollection 2019. Cancer Manag Res. 2019. PMID: 31239773 Free PMC article.
Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy.
Tian MX, Zhou YF, Qu WF, Liu WR, Jin L, Jiang XF, Wang H, Tao CY, Zhou PY, Fang Y, Ding ZB, Peng YF, Zhou J, Fan J, Shi YH. Tian MX, et al. Among authors: zhou j, zhou py, zhou yf. Cancer Immunol Immunother. 2019 Aug;68(8):1369-1378. doi: 10.1007/s00262-019-02371-3. Epub 2019 Jul 23. Cancer Immunol Immunother. 2019. PMID: 31338558 Free PMC article.
Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study.
Zhou PY, Yang CP, Tang Z, Yi Y, Liu WR, Tian MX, Huang JL, Gan W, Jiang XF, Liu G, Wang H, Tao CY, Fang Y, Qu WF, Zhou C, Guan RY, Sun BY, Zhou YF, Song SS, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Gong GZ, Shi YH, Qiu SJ. Zhou PY, et al. Among authors: zhou j, zhou c, zhou yf. Aging (Albany NY). 2019 Dec 12;11(23):11111-11123. doi: 10.18632/aging.102513. Epub 2019 Dec 12. Aging (Albany NY). 2019. PMID: 31829979 Free PMC article.
Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection.
Liu WR, Tian MX, Tang Z, Fang Y, Zhou YF, Song SS, Jiang XF, Wang H, Tao CY, Zhou PY, Qu WF, Ding ZB, Peng YF, Zhou J, Fan J, Shi YH. Liu WR, et al. Among authors: zhou j, zhou py, zhou yf. Br J Cancer. 2020 Jul;123(1):92-100. doi: 10.1038/s41416-020-0864-0. Epub 2020 May 7. Br J Cancer. 2020. PMID: 32376890 Free PMC article.
Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection.
Qu WF, Zhou PY, Liu WR, Tian MX, Jin L, Jiang XF, Wang H, Tao CY, Fang Y, Zhou YF, Song SS, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Fan J, Tang Z, Shi YH. Qu WF, et al. Among authors: zhou j, zhou py, zhou yf. Ann Transl Med. 2020 Apr;8(7):487. doi: 10.21037/atm.2020.03.23. Ann Transl Med. 2020. PMID: 32395531 Free PMC article.
Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
Liu WR, Tian MX, Tao CY, Tang Z, Zhou YF, Song SS, Jiang XF, Wang H, Zhou PY, Qu WF, Fang Y, Ding ZB, Zhou J, Fan J, Shi YH. Liu WR, et al. Among authors: zhou j, zhou py, zhou yf. BMC Cancer. 2020 Jul 10;20(1):642. doi: 10.1186/s12885-020-07138-z. BMC Cancer. 2020. PMID: 32650743 Free PMC article.
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
Fang Y, Liu W, Tang Z, Ji X, Zhou Y, Song S, Tian M, Tao C, Huang R, Zhu G, Jiang X, Gao J, Qu W, Wang H, Zhou P, Wu X, Jin L, Sun H, Ding Z, Peng Y, Zhao S, Zhou J, Fan J, Xu W, Shi Y. Fang Y, et al. Hepatology. 2023 Jan 1;77(1):109-123. doi: 10.1002/hep.32348. Epub 2022 Feb 7. Hepatology. 2023. PMID: 35043976
904 results